1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Influenza - Pipeline Review, H2 2013

Influenza - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 264 pages

Influenza - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Influenza.
- A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Influenza pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Influenza.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Influenza pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Influenza - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Influenza Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Influenza 14
Influenza Therapeutics under Development by Companies 16
Influenza Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 30
Comparative Analysis 30
Mid Clinical Stage Products 31
Comparative Analysis 31
Early Clinical Stage Products 32
Comparative Analysis 32
Discovery and Pre-Clinical Stage Products 33
Comparative Analysis 33
Influenza Therapeutics - Products under Development by Companies 34
Influenza Therapeutics - Products under Investigation by Universities/Institutes 53
Companies Involved in Influenza Therapeutics Development 55
Baxter International Inc. 55
Johnson and Johnson 56
Sanofi-Aventis 57
GlaxoSmithKline plc 58
Inovio Biomedical Corporation 59
MedImmune LLC 60
Daiichi Sankyo Company, Ltd 61
Emergent BioSolutions Inc. 62
Lentigen Corporation 63
Generex Biotechnology Corporation 64
Takeda Pharmaceutical Company Limited 65
Celltrion, Inc. 66
Nanotherapeutics, Inc. 67
Liquidia Technologies, Inc. 68
Biotron Limited 69
Novartis AG 70
Aphios Corporation 71
Novavax, Inc. 72
Toyama Chemical Co. Ltd 73
Vertex Pharmaceuticals Incorporated 74
CEL-SCI Corporation 75
AVI BioPharma Inc. 76
Crucell N.V. 77
OPKO Health, Inc. 78
Zosano Pharma, Inc. 79
4SC AG 80
Hemispherx Biopharma, Inc. 81
Medicago Inc. 82
BioDiem Ltd 83
Mymetics Corporation 84
NanoViricides, Inc. 85
NovaBay Pharmaceuticals, Inc. 86
Medigen Biotechnology Corp. 87
CytoGenix, Inc. 88
Amarillo Biosciences, Inc. 89
BioCryst Pharmaceuticals, Inc. 90
XOMA Ltd. 91
Lipoxen PLC 92
Green Cross Corporation 93
Cytos Biotechnology AG 94
LG Life Sciences, Ltd 95
Synairgen plc 96
Panacea Biotec Limited 97
BioAlliance Pharma SA 98
Eurocine Vaccines AB 99
DiaMedica Inc. 100
Antigen Express, Inc. 101
Functional Genetics, Inc. 102
Colby Pharmaceutical Company 103
Marinomed Biotechnologie GmbH 104
Nutri Pharma ASA 105
LigoCyte Pharmaceuticals, Inc. 106
Mucosis B.V. 107
Evolva SA 108
Quantum Pharmaceuticals 109
Adimmune Corporation 110
Vironova AB 111
ImmunoBiology Limited 112
CureVac GmbH 113
Pt. Bio Farma 114
Isconova AB. 115
TechnoVax, Inc. 116
MacroGenics, Inc. 117
Okairos 118
Viroblock S.A. 119
PDS Biotechnology Corporation 120
AlphaVax, Inc. 121
Innate Therapeutics Limited 122
Vaxin, Inc. 123
EpiVax, Inc. 124
Kineta, Inc. 125
CreatoFlu Laboratories GmbH 126
Indus Biotech Private Limited 127
Romark Laboratories, L.C. 128
Chimerix, Inc. 129
Adamas Pharmaceuticals, Inc. 130
Theraclone Sciences, Inc. 131
REPLICor Inc. 132
Immune Targeting Systems (ITS) Ltd. 133
Sinovac Biotech Ltd. 134
Wittycell S.A.S. 135
Immunotope, Inc. 136
Microbiotix, Inc. 137
NanoBio Corporation 138
Protein Sciences Corporation 139
Shin Nippon Biomedical Laboratories, Ltd. 140
ImmunoVaccine Technologies Inc. 141
VaxInnate Corporation 142
Etubics Corporation 143
Immune Design Inc. 144
NewLink Genetics Corporation 145
Obio Pharmaceutical Holdings Limited. 146
Canopus BioPharma Incorporated 147
UMN Pharma Inc. 148
iBio, Inc. 149
PepTcell Limited 150
BiondVax Pharmaceuticals Ltd. 151
Sirnaomics, Inc. 152
Alios BioPharma, Inc. 153
Vaxart, Inc. 154
Hawaii Biotech, Inc. 155
TaiGen Biotechnology Co., Ltd. 156
Variation Biotechnologies, Inc. 157
IRX Therapeutics, Inc. 158
NexBio, Inc. 159
Serum Institute of India Limited 160
NasVax Ltd. 161
ImmuneRegen BioSciences, Inc. 162
AIMM Therapeutics B.V. 163
Cocrystal Discovery, Inc. 164
Trellis Bioscience, Inc. 165
Selecta Biosciences, Inc. 166
Cilian AG 167
PaxVax 168
AmVac AG 169
TSRL, Inc. 170
Prosetta Corporation 171
Revivicor, Inc. 172
Beech Tree Labs, Inc. 173
Vivaldi Biosciences Inc. 174
Vaxine Pty Ltd 175
Vichem Chemie Research Ltd. 176
APEPTICO Forschung und Entwicklung GmbH 177
VLP Biotech, Inc. 178
AUS Bio Limited 179
AltraVax Inc. 180
Influenza - Therapeutics Assessment 181
Assessment by Monotherapy Products 181
Assessment by Combination Products 182
Assessment by Route of Administration 183
Assessment by Molecule Type 186
Drug Profiles 188
influenza vaccine live - Drug Profile 188
favipiravir - Drug Profile 189
peramivir - Drug Profile 190
NT-300 - Drug Profile 192
laninamivir - Drug Profile 194
influenza virus vaccine - Drug Profile 196
influenza vaccine - Drug Profile 198
prepandemic influenza vaccine (A/H5N1) (whole virion, vero cell derived, inactivated) - Drug Profile 200
GSK-2321138A - Drug Profile 202
GSK-2340273A - Drug Profile 203
zanamivir - Drug Profile 206
influenza vaccine, split virion, inactivated - Drug Profile 208
GSK-2282512A - Drug Profile 209
influenza virus, surface antigen, inactivated - Drug Profile 210
MF59-eH1N1 Influenza Vaccine - Drug Profile 212
Flu Pandemic Vaccine - Drug Profile 213
H5N1 pre-pandemic influenza vaccine - Drug Profile 215
pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - Drug Profile 217
GSK-2833489A - Drug Profile 218
Vaxigrip Quadrivalent - Drug Profile 219
Trivalent Live-Attenuated Influenza Vaccine - Drug Profile 220
KIB-PCI - Drug Profile 222
GC-3102C - Drug Profile 223
AdimFlu-V - Drug Profile 224
Cell Culture-Based Pandemic Influenza Vaccine - Drug Profile 225
Influenza Therapeutics - Drug Profile Updates 226
Influenza Therapeutics - Discontinued Products 240
Influenza Therapeutics - Dormant Products 241
Influenza - Product Development Milestones 254
Featured News and Press Releases 254
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 262
Disclaimer 262



List of Tables

Number of Products Under Development for Influenza, H2 2013 16
Products under Development for Influenza - Comparative Analysis, H2 2013 17
Number of Products under Development by Companies, H2 2013 19
Number of Products under Development by Companies, H2 2013 (Contd..1) 20
Number of Products under Development by Companies, H2 2013 (Contd..2) 21
Number of Products under Development by Companies, H2 2013 (Contd..3) 22
Number of Products under Development by Companies, H2 2013 (Contd..4) 23
Number of Products under Development by Companies, H2 2013 (Contd..5) 24
Number of Products under Development by Companies, H2 2013 (Contd..6) 25
Number of Products under Development by Companies, H2 2013 (Contd..7) 26
Number of Products under Development by Companies, H2 2013 (Contd..8) 27
Number of Products under Development by Companies, H2 2013 (Contd..9) 28
Number of Products under Development by Companies, H2 2013 (Contd..10) 29
Number of Products under Investigation by Universities/Institutes, H2 2013 31
Comparative Analysis by Late Stage Development, H2 2013 32
Comparative Analysis by Mid Clinical Stage Development, H2 2013 33
Comparative Analysis by Early Clinical Stage Development, H2 2013 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 35
Products under Development by Companies, H2 2013 36
Products under Development by Companies, H2 2013 (Contd..1) 37
Products under Development by Companies, H2 2013 (Contd..2) 38
Products under Development by Companies, H2 2013 (Contd..3) 39
Products under Development by Companies, H2 2013 (Contd..4) 40
Products under Development by Companies, H2 2013 (Contd..5) 41
Products under Development by Companies, H2 2013 (Contd..6) 42
Products under Development by Companies, H2 2013 (Contd..7) 43
Products under Development by Companies, H2 2013 (Contd..8) 44
Products under Development by Companies, H2 2013 (Contd..9) 45
Products under Development by Companies, H2 2013 (Contd..10) 46
Products under Development by Companies, H2 2013 (Contd..11) 47
Products under Development by Companies, H2 2013 (Contd..12) 48
Products under Development by Companies, H2 2013 (Contd..13) 49
Products under Development by Companies, H2 2013 (Contd..14) 50
Products under Development by Companies, H2 2013 (Contd..15) 51
Products under Development by Companies, H2 2013 (Contd..16) 52
Products under Development by Companies, H2 2013 (Contd..17) 53
Products under Development by Companies, H2 2013 (Contd..18) 54
Products under Investigation by Universities/Institutes, H2 2013 55
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 56
Baxter International Inc., H2 2013 57
Johnson and Johnson, H2 2013 58
Sanofi-Aventis, H2 2013 59
GlaxoSmithKline plc, H2 2013 60
Inovio Biomedical Corporation, H2 2013 61
MedImmune LLC, H2 2013 62
Daiichi Sankyo Company, Ltd, H2 2013 63
Emergent BioSolutions Inc., H2 2013 64
Lentigen Corporation, H2 2013 65
Generex Biotechnology Corporation, H2 2013 66
Takeda Pharmaceutical Company Limited, H2 2013 67
Celltrion, Inc., H2 2013 68
Nanotherapeutics, Inc., H2 2013 69
Liquidia Technologies, Inc., H2 2013 70
Biotron Limited, H2 2013 71
Novartis AG, H2 2013 72
Aphios Corporation, H2 2013 73
Novavax, Inc., H2 2013 74
Toyama Chemical Co. Ltd, H2 2013 75
Vertex Pharmaceuticals Incorporated, H2 2013 76
CEL-SCI Corporation, H2 2013 77
AVI BioPharma Inc., H2 2013 78
Crucell N.V., H2 2013 79
OPKO Health, Inc., H2 2013 80
Zosano Pharma, Inc., H2 2013 81
4SC AG, H2 2013 82
Hemispherx Biopharma, Inc., H2 2013 83
Medicago Inc., H2 2013 84
BioDiem Ltd, H2 2013 85
Mymetics Corporation, H2 2013 86
NanoViricides, Inc., H2 2013 87
NovaBay Pharmaceuticals, Inc., H2 2013 88
Medigen Biotechnology Corp., H2 2013 89
CytoGenix, Inc., H2 2013 90
Amarillo Biosciences, Inc., H2 2013 91
BioCryst Pharmaceuticals, Inc., H2 2013 92
XOMA Ltd., H2 2013 93
Lipoxen PLC, H2 2013 94
Green Cross Corporation, H2 2013 95
Cytos Biotechnology AG, H2 2013 96
LG Life Sciences, Ltd, H2 2013 97
Synairgen plc, H2 2013 98
Panacea Biotec Limited, H2 2013 99
BioAlliance Pharma SA, H2 2013 100
Eurocine Vaccines AB, H2 2013 101
DiaMedica Inc., H2 2013 102
Antigen Express, Inc., H2 2013 103
Functional Genetics, Inc., H2 2013 104
Colby Pharmaceutical Company, H2 2013 105
Marinomed Biotechnologie GmbH, H2 2013 106
Nutri Pharma ASA, H2 2013 107
LigoCyte Pharmaceuticals, Inc., H2 2013 108
Mucosis B.V., H2 2013 109
Evolva SA, H2 2013 110
Quantum Pharmaceuticals, H2 2013 111
Adimmune Corporation, H2 2013 112
Vironova AB, H2 2013 113
ImmunoBiology Limited, H2 2013 114
CureVac GmbH, H2 2013 115
Pt. Bio Farma, H2 2013 116
Isconova AB., H2 2013 117
TechnoVax, Inc., H2 2013 118
MacroGenics, Inc., H2 2013 119
Okairos, H2 2013 120
Viroblock S.A., H2 2013 121
PDS Biotechnology Corporation, H2 2013 122
AlphaVax, Inc., H2 2013 123
Innate Therapeutics Limited, H2 2013 124
Vaxin, Inc., H2 2013 125
EpiVax, Inc., H2 2013 126
Kineta, Inc., H2 2013 127
CreatoFlu Laboratories GmbH, H2 2013 128
Indus Biotech Private Limited, H2 2013 129
Romark Laboratories, L.C., H2 2013 130
Chimerix, Inc., H2 2013 131
Adamas Pharmaceuticals, Inc., H2 2013 132
Theraclone Sciences, Inc., H2 2013 133
REPLICor Inc., H2 2013 134
Immune Targeting Systems (ITS) Ltd., H2 2013 135
Sinovac Biotech Ltd., H2 2013 136
Wittycell S.A.S., H2 2013 137
Immunotope, Inc., H2 2013 138
Microbiotix, Inc., H2 2013 139
NanoBio Corporation, H2 2013 140
Protein Sciences Corporation, H2 2013 141
Shin Nippon Biomedical Laboratories, Ltd., H2 2013 142
ImmunoVaccine Technologies Inc., H2 2013 143
VaxInnate Corporation, H2 2013 144
Etubics Corporation, H2 2013 145
Immune Design Inc., H2 2013 146
NewLink Genetics Corporation, H2 2013 147
Obio Pharmaceutical Holdings Limited., H2 2013 148
Canopus BioPharma Incorporated, H2 2013 149
UMN Pharma Inc., H2 2013 150
iBio, Inc., H2 2013 151
PepTcell Limited, H2 2013 152
BiondVax Pharmaceuticals Ltd., H2 2013 153
Sirnaomics, Inc., H2 2013 154
Alios BioPharma, Inc., H2 2013 155
Vaxart, Inc., H2 2013 156
Hawaii Biotech, Inc., H2 2013 157
TaiGen Biotechnology Co., Ltd., H2 2013 158
Variation Biotechnologies, Inc., H2 2013 159
IRX Therapeutics, Inc., H2 2013 160
NexBio, Inc., H2 2013 161
Serum Institute of India Limited, H2 2013 162
NasVax Ltd., H2 2013 163
ImmuneRegen BioSciences, Inc., H2 2013 164
AIMM Therapeutics B.V., H2 2013 165
Cocrystal Discovery, Inc., H2 2013 166
Trellis Bioscience, Inc., H2 2013 167
Selecta Biosciences, Inc., H2 2013 168
Cilian AG, H2 2013 169
PaxVax, H2 2013 170
AmVac AG, H2 2013 171
TSRL, Inc., H2 2013 172
Prosetta Corporation, H2 2013 173
Revivicor, Inc., H2 2013 174
Beech Tree Labs, Inc., H2 2013 175
Vivaldi Biosciences Inc., H2 2013 176
Vaxine Pty Ltd, H2 2013 177
Vichem Chemie Research Ltd., H2 2013 178
APEPTICO Forschung und Entwicklung GmbH, H2 2013 179
VLP Biotech, Inc., H2 2013 180
AUS Bio Limited, H2 2013 181
AltraVax Inc., H2 2013 182
Assessment by Monotherapy Products, H2 2013 183
Assessment by Combination Products, H2 2013 184
Assessment by Stage and Route of Administration, H2 2013 187
Assessment by Stage and Molecule Type, H2 2013 189
Influenza Therapeutics - Drug Profile Updates 228
Influenza Therapeutics - Discontinued Products 242
Influenza Therapeutics - Dormant Products 243
Influenza Therapeutics - Dormant Products (Contd..1) 244
Influenza Therapeutics - Dormant Products (Contd..2) 245
Influenza Therapeutics - Dormant Products (Contd..3) 246
Influenza Therapeutics - Dormant Products (Contd..4) 247
Influenza Therapeutics - Dormant Products (Contd..5) 248
Influenza Therapeutics - Dormant Products (Contd..6) 249
Influenza Therapeutics - Dormant Products (Contd..7) 250
Influenza Therapeutics - Dormant Products (Contd..8) 251
Influenza Therapeutics - Dormant Products (Contd..9) 252
Influenza Therapeutics - Dormant Products (Contd..10) 253
Influenza Therapeutics - Dormant Products (Contd..11) 254
Influenza Therapeutics - Dormant Products (Contd..12) 255



List of Figures

Number of Products under Development for Influenza, H2 2013 16
Products under Development for Influenza - Comparative Analysis, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 30
Late Stage Products, H2 2013 32
Mid Clinical Stage Products, H2 2013 33
Early Clinical Stage Products, H2 2013 34
Discovery and Pre-Clinical Stage Products, H2 2013 35
Assessment by Monotherapy Products, H2 2013 183
Assessment by Combination Products, H2 2013 184
Assessment by Route of Administration, H2 2013 185
Assessment by Stage and Route of Administration, H2 2013 186
Assessment by Molecule Type, H2 2013 188
Assessment by Stage and Molecule Type, H2 2013 189



Companies Mentioned

Baxter International Inc.
Johnson and Johnson
Sanofi-Aventis
GlaxoSmithKline plc
Inovio Biomedical Corporation
MedImmune LLC
Daiichi Sankyo Company, Ltd
Emergent BioSolutions Inc.
Lentigen Corporation
Generex Biotechnology Corporation
Takeda Pharmaceutical Company Limited
Celltrion, Inc.
Nanotherapeutics, Inc.
Liquidia Technologies, Inc.
Biotron Limited
Novartis AG
Aphios Corporation
Novavax, Inc.
Toyama Chemical Co. Ltd
Vertex Pharmaceuticals Incorporated
CEL-SCI Corporation
AVI BioPharma Inc.
Crucell N.V.
OPKO Health, Inc.
Zosano Pharma, Inc.
4SC AG
Hemispherx Biopharma, Inc.
Medicago Inc.
BioDiem Ltd
Mymetics Corporation
NanoViricides, Inc.
NovaBay Pharmaceuticals, Inc.
Medigen Biotechnology Corp.
CytoGenix, Inc.
Amarillo Biosciences, Inc.
BioCryst Pharmaceuticals, Inc.
XOMA Ltd.
Lipoxen PLC
Green Cross Corporation
Cytos Biotechnology AG
LG Life Sciences, Ltd
Synairgen plc
Panacea Biotec Limited
BioAlliance Pharma SA
Eurocine Vaccines AB
DiaMedica Inc.
Antigen Express, Inc.
Functional Genetics, Inc.
Colby Pharmaceutical Company
Marinomed Biotechnologie GmbH
Nutri Pharma ASA
LigoCyte Pharmaceuticals, Inc.
Mucosis B.V.
Evolva SA
Quantum Pharmaceuticals
Adimmune Corporation
Vironova AB
ImmunoBiology Limited
CureVac GmbH
Pt. Bio Farma
Isconova AB.
TechnoVax, Inc.
MacroGenics, Inc.
Okairos
Viroblock S.A.
PDS Biotechnology Corporation
AlphaVax, Inc.
Innate Therapeutics Limited
Vaxin, Inc.
EpiVax, Inc.
Kineta, Inc.
CreatoFlu Laboratories GmbH
Indus Biotech Private Limited
Romark Laboratories, L.C.
Chimerix, Inc.
Adamas Pharmaceuticals, Inc.
Theraclone Sciences, Inc.
REPLICor Inc.
Immune Targeting Systems (ITS) Ltd.
Sinovac Biotech Ltd.
Wittycell S.A.S.
Immunotope, Inc.
Microbiotix, Inc.
NanoBio Corporation
Protein Sciences Corporation
Shin Nippon Biomedical Laboratories, Ltd.
ImmunoVaccine Technologies Inc.
VaxInnate Corporation
Etubics Corporation
Immune Design Inc.
NewLink Genetics Corporation
Obio Pharmaceutical Holdings Limited.
Canopus BioPharma Incorporated
UMN Pharma Inc.
iBio, Inc.
PepTcell Limited
BiondVax Pharmaceuticals Ltd.
Sirnaomics, Inc.
Alios BioPharma, Inc.
Vaxart, Inc.
Hawaii Biotech, Inc.
TaiGen Biotechnology Co., Ltd.
Variation Biotechnologies, Inc.
IRX Therapeutics, Inc.
NexBio, Inc.
Serum Institute of India Limited
NasVax Ltd.
ImmuneRegen BioSciences, Inc.
AIMM Therapeutics B.V.
Cocrystal Discovery, Inc.
Trellis Bioscience, Inc.
Selecta Biosciences, Inc.
Cilian AG
PaxVax
AmVac AG
TSRL, Inc.
Prosetta Corporation
Revivicor, Inc.
Beech Tree Labs, Inc.
Vivaldi Biosciences Inc.
Vaxine Pty Ltd
Vichem Chemie Research Ltd.
APEPTICO Forschung und Entwicklung GmbH
VLP Biotech, Inc.
AUS Bio Limited
AltraVax Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.